How Long Has Leqvio Been on the Market? Since 2021
Leqvio (inclisiran) received FDA approval on December 22, 2021, making it available for roughly three years as the first siRNA therapy targeting PCSK9.
Inclisiran: Regulatory History
8 source-based articles maintained by the HealthRX.com Editorial Team.
8articles
5topic areas covered
May 25, 2026latest review
Inclisiran: Regulatory History library
Showing 8 of 8 clinical reviews.
Inclisiran Cardiovascular Outcomes: ORION-4 and Label Updates
ORION-4 outcomes data isn't yet confirmed on the current Leqvio label; see the 2020-2026 FDA/EMA timeline and where to verify exact label text.
Inclisiran EMA Approval vs FDA: Key Differences
EMA approved inclisiran (Leqvio) in December 2020, a year before the FDA. Compare label indications, patient populations, and outcomes trial requirements.
Inclisiran Launch: FDA History, ORION-4 and Next-Gen Pipeline
Inclisiran (Leqvio) launched Dec 2021 as the first PCSK9 siRNA. ORION-4 outcomes data expected mid-2026, with next-gen siRNA candidates now in early development.
Leqvio (Inclisiran) FAERS Safety Signals: Post-Market Surveillance Data and What It Means
A clinical review of Leqvio (inclisiran) FDA Adverse Event Reporting System (FAERS) safety signals, post-market surveillance findings, label updates, and real-world safety data from ORION trials and beyond.
Leqvio (Inclisiran) Legal and Patent Challenges
A clinical review of the legal, patent, and regulatory challenges facing Leqvio (inclisiran), including FDA approval history, label updates, litigation risks, and post-market safety surveillance.
Leqvio J-Code Status and Global Regulatory Approvals
Leqvio has no unique J-code yet; billed under JCode Q9992/temporary codes. See FDA (2021), EMA (2020) approvals and label details for 70+ countries.
Why Is Leqvio Under Medicare Part B, Not Part D?
Leqvio is physician-administered, not self-injected or pharmacy-dispensed, so Medicare covers it under Part B. It cannot legally be compounded under Part D rules.